Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: Saulamanca who wrote (1223)	6/26/2007 9:19:02 PM
From: tuck	Respond to of 3661

Nuvo off 17% after hours on Bayer officially terminating the alfimeprase alliance: Message 23654591 Though it could opt back in for a song. Again, unless NUVO can get the FDA to agree to some easier endpoints, further study of Alfimeprase isn't going to do anything but eat resources, IMO. I don't know how many folks they had enrolled, perhaps completing NAPA-3 & SONOMA-3 wouldn't take that much dough, if the FDA will let them do it. NUVO has almost no debt, and if this AH price action holds, it will be trading near cash. But to be a value play in my eyes, they would have to drop alfimeprase and rNAPc2, and restructure into an early stage development company. Some of their early stuff looks interesting. In other words, I'm not a buyer on this firesale. But will keep an eye on it. Cheers, Tuck